Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Compugen Ltd.
  6. News
  7. Summary
    CGEN   IL0010852080

COMPUGEN LTD.

(CGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Compugen Ltd. Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902

10/04/2021 | 07:00am EST

Compugen Ltd. announced that Compugen is entitled to receive a $6 million milestone payment from AstraZeneca triggered by the dosing of the first patient in a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer. AZD2936 is derived from COM902, Compugen's high-affinity clinical-stage anti-TIGIT antibody. In 2018, Compugen and AstraZeneca entered into an agreement by which Compugen provided an exclusive license to AstraZeneca to use Compugen's monospecific antibodies that bind to TIGIT, including COM902, for the development of bi-specific and multi-specific antibody products, excluding such bi-specific and multi-specific antibodies that also bind to PVRIG, PVRL2 and/or TIGIT. AstraZeneca is responsible for all research, development, and commercial activities. AstraZeneca has the right to create multiple products under this license. To date, Compugen has received a $10 million upfront payment, an additional $2 million milestone payment and is entitled to an additional $6 million payment triggered by this first patient being dosed, out of up to an aggregate milestone amount of $200 million that the Company is eligible to receive in development, regulatory and commercial milestones for the first product, as well as tiered royalties on future product sales. If additional products are developed based on Compugen's monospecific antibodies that bind to TIGIT, additional milestones and royalties would be due to Compugen.


ę S&P Capital IQ 2021
All news about COMPUGEN LTD.
11/29Compugen Wins Fortinet Achievement Award at NSE XPERTS Summit 2021
AQ
11/15Oppenheimer Adjusts Compugen PT to $17 From $19, Maintains Outperform Rating
MT
11/12COMPUGEN : Q3 Earnings Snapshot
AQ
11/12Compugen Narrows Net Loss in Q3, Revenue Gains on Milestone Payment
MT
11/12Press Release dated November 12, 2021 – “Compugen Presents Preliminary Resu..
PU
11/12Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Mill..
PU
11/12Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy Study of..
PR
11/12Compugen Presents Initial Translational Data Supporting the Differentiation of PVRIG Co..
PR
11/12Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 wi..
PR
11/12Compugen Reports Third Quarter 2021 Results
PR
More news
Analyst Recommendations on COMPUGEN LTD.
More recommendations
Financials (USD)
Sales 2021 7,00 M - -
Net income 2021 -36,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -9,53x
Yield 2021 -
Capitalization 359 M 359 M -
Capi. / Sales 2021 51,2x
Capi. / Sales 2022 -
Nbr of Employees 68
Free-Float 94,2%
Chart COMPUGEN LTD.
Duration : Period :
Compugen Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COMPUGEN LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 4,16 $
Average target price 20,57 $
Spread / Average Target 395%
EPS Revisions
Managers and Directors
Anat Cohen-Dayag President, Chief Executive Officer & Director
Ari Krashin Chief Operating & Financial Officer
Paul Jai Sekhri Chairman
Henry Adewoye Chief Medical Officer
Arie Ovadia Director
Sector and Competitors
1st jan.Capi. (M$)
COMPUGEN LTD.-64.33%359
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298